Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.
作者： Stefania Rocca , Giovanna Carrà , Pietro Poggio , Alessandro Morotti , Mara Brancaccio
DOI: 10.1186/S12943-018-0774-4
关键词:
摘要: Atypical Chronic Myeloid Leukemia (aCML) is a myeloproliferative neoplasm characterized by neutrophilic leukocytosis and dysgranulopoiesis. From a genetic point of view, aCML …
biomedcentral.com
springer.com
sci-hub.se 参考文章(153)
Federica Fusella, Roberta Ferretti, Daniele Recupero, Stefania Rocca, Augusta Di Savino, Giusy Tornillo, Lorenzo Silengo, Emilia Turco, Sara Cabodi, Paolo Provero, Pier Paolo Pandolfi, Anna Sapino, Guido Tarone, Mara Brancaccio, Morgana acts as a proto‐oncogene through inhibition of a ROCK–PTEN pathway The Journal of Pathology. ,vol. 234, pp. 152- 163 ,(2014) , 10.1002/PATH.4341
Jason L. Freedman, Ami V. Desai, L. Charles Bailey, Richard Aplenc, Bettina Burnworth, Barbara K. Zehentner, David T. Teachey, Gerald Wertheim, Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. Pediatric Blood & Cancer. ,vol. 63, pp. 156- 159 ,(2016) , 10.1002/PBC.25694
Razelle Kurzrock, Carlos E. Bueso-Ramos, Hagop Kantarjian, Emil Freireich, Susan L. Tucker, Michael Siciliano, Susan Pilat, Moshe Talpaz, BCR Rearrangement–Negative Chronic Myelogenous Leukemia Revisited Journal of Clinical Oncology. ,vol. 19, pp. 2915- 2926 ,(2001) , 10.1200/JCO.2001.19.11.2915
Angelika Berger, Veronika Sexl, Peter Valent, Richard Moriggl, Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia Oncotarget. ,vol. 5, pp. 9564- 9576 ,(2014) , 10.18632/ONCOTARGET.2465
Michael Deininger, Jerald Radich, Timothy C. Burn, Reid Huber, Dilan Paranagama, Srdan Verstovsek, The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis Blood. ,vol. 126, pp. 1551- 1554 ,(2015) , 10.1182/BLOOD-2015-03-635235
M Meggendorfer, U Bacher, T Alpermann, C Haferlach, W Kern, C Gambacorti-Passerini, T Haferlach, S Schnittger, SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. ,vol. 27, pp. 1852- 1860 ,(2013) , 10.1038/LEU.2013.133
Nan Li, Anliu Tang, Shuo Huang, Zeng Li, Xiayu Li, Shourong Shen, Jian Ma, Xiaoyan Wang, MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway Molecular and Cellular Biochemistry. ,vol. 380, pp. 107- 119 ,(2013) , 10.1007/S11010-013-1664-0
Morgan L McLemore, Satkiran Grewal, Fulu Liu, Angela Archambault, Jennifer Poursine-Laurent, Jeff Haug, Daniel C Link, None, STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity. ,vol. 14, pp. 193- 204 ,(2001) , 10.1016/S1074-7613(01)00101-7
J Burthem, K Rees-Unwin, R Mottram, J Adams, G S Lucas, E Spooncer, A D Whetton, The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia. ,vol. 21, pp. 1708- 1714 ,(2007) , 10.1038/SJ.LEU.2404762
J Gits, D van Leeuwen, H P Carroll, I P Touw, A C Ward, Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia. ,vol. 20, pp. 2111- 2118 ,(2006) , 10.1038/SJ.LEU.2404448